Fennec Pharmaceuticals Inc. (FENC) Financial Ratios
25 years of historical data (2000–2024) · Healthcare · Biotechnology
EV/EBITDA
55.32
+13% vs avg
5yr avg: 49.05
30Y Low49.1·High49.1
P/FCF
7.18
+12% vs avg
5yr avg: 6.39
30Y Low6.4·High6.4
P/B Ratio
↑
N/A
—
5yr avg: 6.66
30Y Low5.6·High10.9
ROE
↓
N/A
—
5yr avg: -170.0%
30Y Low-355%·High-36%
Debt/EBITDA
5.74
+0% vs avg
5yr avg: 5.74
30Y Low5.7·High5.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
FENC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Fennec Pharmaceuticals Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 7.2x P/FCF, 12% above the 5-year average of 6.4x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $194M | $172M | $298M | $252M | $114M | $177M | $129M | $121M | $150M | — | — |
| Enterprise Value | $186M | $165M | $316M | $253M | $98M | $146M | $115M | $99M | $122M | — | — |
| P/E Ratio → | -431.25 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.07 | 3.63 | 14.03 | 171.11 | — | 1038.79 | — | — | — | — | — |
| P/B Ratio | — | — | — | — | 7.26 | 6.07 | 10.87 | 5.69 | 5.62 | — | — |
| P/FCF | 7.18 | 6.39 | — | — | — | — | — | — | — | — | — |
| P/OCF | 7.18 | 6.39 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
FENC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Fennec Pharmaceuticals Inc.'s enterprise value stands at 55.3x EBITDA, 13% above its 5-year average of 49.1x. The Healthcare sector median is 14.5x, placing the stock at a 283% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.48 | 14.86 | 171.87 | — | 860.30 | — | — | — | — | — |
| EV / EBITDA | 55.32 | 49.05 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 72.56 | 41.32 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 6.12 | — | — | — | — | — | — | — | — | — |
FENC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Fennec Pharmaceuticals Inc. earns an operating margin of 5.4%. Operating margins have expanded from -1471.6% to 5.4% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.3% | 93.3% | 94.1% | 94.4% | — | 100.0% | — | — | — | — | — |
| Operating Margin | 5.4% | 5.4% | -60.1% | -1471.6% | — | -10520.6% | — | — | — | — | — |
| Net Profit Margin | -0.9% | -0.9% | -75.5% | -1544.9% | — | -10652.4% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -345.0% | -76.7% | -88.5% | -78.8% | -41.1% | -46.5% | -135.5% | -113.5% |
| ROA | -1.2% | -1.2% | -59.6% | -92.3% | -63.9% | -79.5% | -70.5% | -38.5% | -43.5% | -111.8% | -38.9% |
| ROIC | — | — | -414.7% | — | — | — | — | — | — | — | — |
| ROCE | 9.0% | 9.0% | -61.3% | -100.7% | -68.5% | -87.4% | -80.2% | -43.3% | -45.8% | -139.4% | -325.6% |
FENC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Fennec Pharmaceuticals Inc. carries a Debt/EBITDA ratio of 5.7x, which is highly leveraged (74% above the sector average of 3.3x). The company holds a net cash position — cash of $27M exceeds total debt of $19M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of just 0.6x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.32 | — | — | — | — | — | — |
| Debt / EBITDA | 5.74 | 5.74 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -1.02 | -1.04 | -1.15 | -1.07 | -1.06 | -1.10 | -1.72 |
| Net Debt / EBITDA | -2.17 | -2.17 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.27 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 0.63 | 0.63 | -3.76 | -22.18 | -135.49 | — | — | — | — | — | — |
Net cash position: cash ($27M) exceeds total debt ($19M)
FENC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Fennec Pharmaceuticals Inc.'s current ratio of 6.38x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.80x to 6.38x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.38 | 6.38 | 3.56 | 5.80 | 13.54 | 13.39 | 6.11 | 14.02 | 17.28 | 9.88 | 2.16 |
| Quick Ratio | 6.22 | 6.22 | 3.27 | 5.67 | 13.54 | 13.39 | 6.11 | 14.02 | 17.28 | 9.88 | 2.16 |
| Cash Ratio | 3.85 | 3.85 | 1.76 | 5.16 | 12.76 | 12.93 | 6.01 | 13.92 | 17.19 | 9.77 | 2.00 |
| Asset Turnover | — | 1.06 | 0.79 | 0.05 | — | 0.01 | — | — | — | — | — |
| Inventory Turnover | 3.00 | 3.00 | 0.58 | 0.14 | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 98.92 | 151.38 | 382.54 | — | — | — | — | — | — | — |
FENC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Fennec Pharmaceuticals Inc. returns 0.1% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 13.9% | 15.6% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $27M | $27M | $26M | $26M | $24M | $20M | $19M | $15M | $13M | $11M |
Peer Comparison
Compare FENC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 FENCYou | $194M | -431.3 | 55.3 | 7.2 | 93.3% | 5.4% | — | — | 5.7 |
 LCTX | $333M | -4.9 | — | — | — | -251.6% | -105.6% | -141.9% | — |
 SNOA | $2M | -0.4 | — | — | 38.2% | -26.0% | -65.5% | -188.1% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 JAZZ | $14B | -38.9 | 23.8 | 11.0 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 25 years · Updated daily
See FENC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FENC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FENC vs LCTX
Side-by-side business, growth, and profitability comparison vs Lineage Cell Therapeutics, Inc..
Start ComparisonFENC — Frequently Asked Questions
Quick answers to the most common questions about buying FENC stock.
What is Fennec Pharmaceuticals Inc.'s P/E ratio?
Fennec Pharmaceuticals Inc.'s current P/E ratio is -431.3x. This places it at the 50th percentile of its historical range.
What is Fennec Pharmaceuticals Inc.'s EV/EBITDA?
Fennec Pharmaceuticals Inc.'s current EV/EBITDA is 55.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 49.1x.
Is FENC stock overvalued?
Based on historical data, Fennec Pharmaceuticals Inc. is trading at a P/E of -431.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Fennec Pharmaceuticals Inc.'s profit margins?
Fennec Pharmaceuticals Inc. has 93.3% gross margin and 5.4% operating margin.
How much debt does Fennec Pharmaceuticals Inc. have?
Fennec Pharmaceuticals Inc.'s Debt/EBITDA ratio is 5.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.